An Overview of the Most Recent Studies in Multiple Myeloma | Claudio Cerchione, MD, PhD

An Overview of the Most Recent Studies in Multiple Myeloma | Claudio Cerchione, MD, PhD

Daratumumab + lenalidomide vs lenalidomide as myeloma maintenance | Mitul Gandhi, MD

Daratumumab + lenalidomide vs lenalidomide as myeloma maintenance | Mitul Gandhi, MD

Updates on Ramantamig, a Myeloma Trispecific Antibody | Mark Wildgust, PhD

Updates on Ramantamig, a Myeloma Trispecific Antibody | Mark Wildgust, PhD

Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD

Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD

Multidisciplinary approaches to improve prognosis prediction | Claudio Cerchione, MD, PhD

Multidisciplinary approaches to improve prognosis prediction | Claudio Cerchione, MD, PhD

Amyloidosis and immune profling in AL and ATTR amyloidosis | Philip McCarthy, MD

Amyloidosis and immune profling in AL and ATTR amyloidosis | Philip McCarthy, MD

Taste Changes from Talquetamab -Talisman Study Insights | Rakesh Popat, PhD

Taste Changes from Talquetamab -Talisman Study Insights | Rakesh Popat, PhD

Duffy Null- Could a Simple Blood Test Guide Your Myeloma Treatment? | Lauren Merz, MD

Duffy Null- Could a Simple Blood Test Guide Your Myeloma Treatment? | Lauren Merz, MD

Advances in supportive care for multiple myeloma | Artur Jurczyszyn, MD

Advances in supportive care for multiple myeloma | Artur Jurczyszyn, MD

Hypomethylating agent for newly diagnosed TP53-mutant AML | Talher Badar, MBBS, MD

Hypomethylating agent for newly diagnosed TP53-mutant AML | Talher Badar, MBBS, MD